Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Other Events

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Other Events

Story continues below

Item8.01

Other Events.

On June3, 2017, Agios Pharmaceuticals, Inc. (the Company) issued
a press release announcing updated clinical data from the
dose-escalation and expansion cohorts of the Companys ongoing
Phase 1 study evaluating single agent AG-120 (ivosidenib) in
patients with isocitrate dehydrogenase-1 mutant positive
cholangiocarcinoma. On June6, 2017, the Company and Celgene
Corporation issued a press release announcing new efficacy and
safety data from the ongoing Phase 1 dose-escalation and
expansion study evaluating investigational oral IDHIFA
(enasidenib) in patients with relapsed or refractory acute
myeloid leukemia with an isocitrate dehydrogenase-2 mutation. The
Company and Celgene presented these data at the American Society
of Clinical Oncology (ASCO) Annual Meeting held June2-6, 2017 in
Chicago, Illinois.

The full text of the press releases issued in connection with
these announcements are attached as Exhibit 99.1 and Exhibit 99.2
to this Current Report on Form 8-K and incorporated herein by
reference.

Item9.01 Financial Statements and Exhibits.

(d) The following exhibits are included in this report:

ExhibitNo.

Description

99.1 Press release issued by Agios Pharmaceuticals, Inc. on June
3, 2017.
99.2 Press release issued by Agios Pharmaceuticals, Inc. and
Celgene Corporation on June 6, 2017.


About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

An ad to help with our costs